Preclinical and clinical studies have demonstrated that therapies targeting the heparanase /syndecan-1 axis are promising for blocking aggressive cancer phenotypes [26], which could lead to HCC treatments in the future. Here, HPSE is linked to hepatocellular carcinoma.